Ocular FIP evidence grows as antiviral treatment guidance evolves

Ocular feline infectious peritonitis is moving from a poorly characterized complication to a more actionable treatment category, as new evidence adds detail on how cats with eye involvement respond to antiviral therapy. A 2025 observational case series reported outcomes in 20 cats with ocular FIP treated with remdesivir alone or in combination with GS-441524, helping address a part of the disease spectrum that earlier FIP treatment studies had not described in depth. (pubmed.ncbi.nlm.nih.gov)

That update lands in the middle of a broader FIP treatment shift. Before antivirals, FIP was widely regarded as almost uniformly fatal once clinical signs appeared. Over the past several years, GS-441524 and remdesivir have changed that outlook, first through case reports and field studies, then through larger retrospective series and systematic review data. A 2025 systematic review covering 2018-2024 literature reported an overall treatment success rate of 84.6% for GS-441524-treated cats, while noting that outcomes were influenced by disease form and that neurologic cases tended to do worse than less complicated presentations. That aligns with recent clinical commentary describing real-world response rates in the roughly 85% to 90% range as antiviral use has expanded and protocols have matured. (pubmed.ncbi.nlm.nih.gov)

For ocular disease specifically, the evidence base has been thinner. Earlier literature established that FIP can involve both the central nervous system and the eye, and a 2020 report on neurologic FIP included ocular imaging in one treated cat, supporting the idea that GS-441524 can reach and improve these harder-to-treat compartments. More recent guidance now groups ocular and neurologic FIP together as presentations that often need more aggressive antiviral dosing because of blood-eye and blood-brain barrier considerations. The 2025 ABCD FIP guideline cites higher remdesivir dosing for ocular or neurologic disease, including divided dosing at the upper end of the range in some cases, and notes that oral GS-441524 is generally preferred when available. Practical education aimed at clinicians has reinforced the same point: ocular involvement is not just a secondary finding but can be the dominant presentation, particularly in non-effusive FIP, where eye and neurologic signs are more common than in wet disease. (pubmed.ncbi.nlm.nih.gov)

That clinical framing matters because ocular FIP can present in ways that are easy to miss if veterinarians are focused mainly on effusions or systemic decline. Reported anterior segment findings include keratic precipitates, iris color change, dyscoria or anisocoria, hyphema, hypopyon, and fibrinous aqueous exudate. Posterior segment findings can include tapetal or non-tapetal retinal lesions, retinal hemorrhage, vascular tortuosity, retinal detachment, and perivascular cuffing or effusion. Signs may be unilateral or bilateral, and in some cats they are the first clue to underlying systemic FIP rather than a late complication.

The regulatory and market context has changed, too. In the U.S., Cornell’s Feline Health Center said Stokes Pharmacy, working with Bova, announced on May 30, 2024 that compounded oral GS-441524 would become available starting June 1, 2024. Around the same time, FDA said it did not intend to enforce new animal drug approval requirements for patient-specific compounded GS-441524 prescribed by a veterinarian for FIP under the conditions in Guidance for Industry #256, while also emphasizing that compounded animal drugs are still unapproved and that office-stock compounding would require nomination of the bulk substance. (vet.cornell.edu)

That distinction matters because access has long been entangled with quality concerns. A JAVMA study of unlicensed antiviral products used at home for FIP found that injectable formulations generally contained more GS-441524 than advertised and had very low pH, while oral formulations showed wider variability, with many containing substantially more or less drug than labeled. For veterinarians, the move toward regulated, patient-specific compounding doesn't solve every clinical question, but it does create a more defensible framework for prescribing and monitoring treatment. (pubmed.ncbi.nlm.nih.gov)

At the same time, clinicians are starting to look beyond whether treatment works to how protocols might be refined. A 2025 JSAP study discussed in continuing education coverage evaluated high-dose induction therapy, treatment duration, and possible stopping criteria using acute phase proteins and routine clinicopathologic trends. The rationale was straightforward: many cats improve clinically within about a week of starting antivirals, but early appetite and weight gain do not necessarily mean the virus has been cleared, especially from harder-to-penetrate sites such as the eye and CNS. Investigators examined serum amyloid A, alpha-1 acid glycoprotein, and albumin:globulin ratio as more objective markers that might help guide when treatment can be safely discontinued, potentially shortening therapy in selected cases while avoiding premature stopping.

Industry and expert commentary has broadly reflected cautious optimism. Cornell framed legal U.S. access to compounded GS-441524 as a major step forward for a previously devastating disease. Meanwhile, international guidance has become more practical and less theoretical, focusing on induction strategies, switching between remdesivir and GS-441524, adverse-effect management, and the reality that many cats can now be treated successfully when therapy starts promptly and is tailored to disease severity. Broader clinical education has also emphasized that diagnosis in practice remains largely presumptive rather than definitive, so treatment decisions still depend on combining signalment, clinicopathologic clues, imaging, effusion analysis when present, and compatible ocular or neurologic findings rather than waiting for perfect confirmation. (vet.cornell.edu)

Why it matters: For veterinary professionals, the ocular FIP conversation is shifting from whether treatment is possible to how best to treat, monitor, and counsel. Ocular signs may point to a more complicated FIP phenotype, and current evidence suggests these cats may need higher-intensity protocols, closer reassessment, and realistic discussions with pet parents about duration, route of administration, relapse risk, and cost. The newer ocular case series doesn't settle the standard of care, but it does strengthen the case that eye involvement should trigger deliberate antiviral planning rather than therapeutic pessimism. It also reinforces a practical point emerging across recent education and guideline updates: visible early improvement is encouraging, but treatment decisions should still be anchored to disease form, response trends, and objective monitoring where possible. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next developments are likely to be more detailed ocular-specific outcome data, clearer dosing algorithms for eye and CNS involvement, and further normalization of legal prescribing pathways in the U.S., especially as guidelines incorporate newer case series and clinicians gain experience with compounded products. Another area to watch is whether higher-dose induction and biomarker-guided stopping criteria can safely reduce treatment duration without increasing relapse risk, particularly in cats with ocular or neurologic disease. (pubmed.ncbi.nlm.nih.gov)